Lior Carmon
Chief Investment Officer bei Van Leer Xenia Ventures
Aktive Positionen von Lior Carmon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Israel Immunological Society | Direktor/Vorstandsmitglied | - | - |
Van Leer Xenia Ventures
Van Leer Xenia Ventures Investment ManagersFinance Van Leer Xenia Ventures (Van Leer Xenia Ventures) is a venture capital firm founded in 2006. The firm is headquartered in Jerusalem, Israel. | Chief Investment Officer | - | - |
Private Equity Investor | - | - | |
Sakura Bio
Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Direktor/Vorstandsmitglied | 01.10.2022 | - |
Karriereverlauf von Lior Carmon
Ehemalige bekannte Positionen von Lior Carmon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VAXIL BIO LTD. | Direktor/Vorstandsmitglied | - | 04.01.2017 |
Vaxil Bio Ltd. /Old/
Vaxil Bio Ltd. /Old/ BiotechnologyHealth Technology Vaxil Bio Ltd. is a clinical stage biotechnology company which engages in the development of synthetic therapeutic and preventive vaccines. It operates through the Cancer and Tuberculosis therapeutic areas. The Cancer area comprises vaccines for metastatic breast cancer patients in combination with hormonal therapy. The Tuberculosis area involves vaccines to boost immunity in BCG immunized patients and as a theraputic vaccine in TB patients. The company was founded by Lior Carmen and Julian Levy on August 6, 2006 and is headquartered in Nes-Ziona, Israel. | Direktor/Vorstandsmitglied | 06.08.2006 | - |
Vorstandsvorsitzender | 06.08.2006 | - | |
Technik-/Wissenschafts-/F&E-Leiter | 06.08.2006 | - | |
Gründer | 06.08.2006 | - |
Ausbildung von Lior Carmon
Ben-Gurion University of the Negev | Masters Business Admin |
Weizmann Institute of Science | Doctorate Degree |
Statistik
International
Israel | 7 |
Kanada | 2 |
Operativ
Director/Board Member | 4 |
Chief Executive Officer | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
VAXIL BIO LTD. | Health Technology |
Private Unternehmen | 4 |
---|---|
Vaxil Bio Ltd. /Old/
Vaxil Bio Ltd. /Old/ BiotechnologyHealth Technology Vaxil Bio Ltd. is a clinical stage biotechnology company which engages in the development of synthetic therapeutic and preventive vaccines. It operates through the Cancer and Tuberculosis therapeutic areas. The Cancer area comprises vaccines for metastatic breast cancer patients in combination with hormonal therapy. The Tuberculosis area involves vaccines to boost immunity in BCG immunized patients and as a theraputic vaccine in TB patients. The company was founded by Lior Carmen and Julian Levy on August 6, 2006 and is headquartered in Nes-Ziona, Israel. | Health Technology |
Israel Immunological Society | |
Van Leer Xenia Ventures
Van Leer Xenia Ventures Investment ManagersFinance Van Leer Xenia Ventures (Van Leer Xenia Ventures) is a venture capital firm founded in 2006. The firm is headquartered in Jerusalem, Israel. | Finance |
Sakura Bio
Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Health Technology |
- Börse
- Insiders
- Lior Carmon
- Erfahrung